Ignite Creation Date:
2024-05-05 @ 5:03 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00371774
Status:
COMPLETED
Last Update Posted:
2011-11-17
First Post:
2006-08-31
Brief Title:
Amevive Wisdom Acquired From Real-Time Evidence AWARE Program
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
Amevive Wisdom Acquired From Real-Time Evidence AWARE Program
Status:
COMPLETED
Status Verified Date:
2011-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Purpose
To develop a real time national clinical database to support and share best practices
1 To generate hypotheses for future clinical research
2 To understand how AMEVIVE is used in routine clinical practicereal world setting
Each patient visit will include the following observational endpoints
1 AMEVIVE dosing
2 Number of courses
3 Concomitant treatment
4 Response to treatment patient and physician global assessments
5 Status of other psoriasis-related medical conditions
6 Time to re-treatment
To develop a real time national clinical database to support and share best practices
1 To generate hypotheses for future clinical research
2 To understand how AMEVIVE is used in routine clinical practicereal world setting
Each patient visit will include the following observational endpoints
1 AMEVIVE dosing
2 Number of courses
3 Concomitant treatment
4 Response to treatment patient and physician global assessments
5 Status of other psoriasis-related medical conditions
6 Time to re-treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None